Who are Latanoprost ophthalmic solution 0.005%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Travatan, Lumigan, Xalatan, Cytotec, Caverject, Hemabate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/latanoprost-ophthalmic-solution-0-005.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Latanoprost ophthalmic solution 0.005% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Latanoprost ophthalmic solution 0.005% (Latanoprost ophthalmic solution 0.005%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin Analog [EPC].

marketed Prostaglandin Analog [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

Latanoprost ophthalmic solution 0.005% (Latanoprost ophthalmic solution 0.005%) — Aerie Pharmaceuticals.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Latanoprost ophthalmic solution 0.005% TARGET	Latanoprost ophthalmic solution 0.005%	Aerie Pharmaceuticals	marketed	Prostaglandin Analog [EPC]
Travatan	TRAVOPROST		marketed	Prostaglandin Analog [EPC]	Prostaglandin F2-alpha receptor	2001-01-01
Lumigan	BIMATOPROST		marketed	Prostaglandin Analog [EPC]	Aldo-keto reductase family 1 member C3	2001-01-01
Xalatan	LATANOPROST	Thea Pharma	marketed	Prostaglandin Analog [EPC]	Prostaglandin F2-alpha receptor	1996-01-01
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Caverject	ALPROSTADIL	Pfizer	marketed	Prostaglandin Analog [EPC]	Prostaglandin E2 receptor EP3 subtype	1981-01-01
Hemabate	CARBOPROST	Pfizer	marketed	Prostaglandin Analog	Prostaglandin F2-alpha receptor	1979-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin Analog [EPC] class)

· 2 drugs in this class
Pfizer · 2 drugs in this class
Aerie Pharmaceuticals · 1 drug in this class
Thea Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Latanoprost ophthalmic solution 0.005% — Competitive Intelligence Brief. https://druglandscape.com/ci/latanoprost-ophthalmic-solution-0-005. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab